Trial Profile
A Retrospective Study Evaluating the Relationship between Early Changes in Disease Specific Light Chains and Depth/Duration of Hematologic Responses in Amyloidosis Patients Treated with Daratumumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 29 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.